Searchable abstracts of presentations at key conferences in endocrinology

ea0022p866 | Thyroid | ECE2010

Selenium and pentoxifylline in patients with mild Graves’ orbitopathy: Results of a randomized placebo-controlled double-blind clinical trial

Marcocci Claudio , Altea Maria Antonietta , Kahaly George , Pitz Susanne , Krassas Gerasimos , Boboridia Kostas , Bartalena Luigi , Sivelli Mario , von Arx Georg , Stahl Matthias , Nardi Marco , Mourits Maarten , Baldeschi Leilo , Pinchera Also , Wiersinga Wilmar , EUGOGO Group

We studied 152 patients with GravesÂ’ disease mild orbitopathy (GO), with a disease duration of <18 months, who had been euthyroid for at least 2 months after antithyroid drug or surgery, or 6 months after 131-Iodine. No patient received previous treatment for GO, except for local measures. Patients were randomized to receive either selenium (SE), an antioxidant (as selenium selenite, 100 (g b.i.d), or pentoxifylline (PF), an anti-inflammatory and antifibrotic agent (6...